Stocks: Baxter International Inc (BAX) Receives Consensus Rating of “Buy” from Brokerages

Stocks: Baxter International Inc (BAX) Receives Consensus Rating of “Buy” from Brokerages

Baxter International Inc (NYSE:BAX) has been assigned an average rating of “Buy” from the thirteen analysts that are currently covering the stock. One investment analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $57.80.

A number of equities research analysts have issued reports on BAX shares. Zacks Investment Research raised Baxter International from a “hold” rating to a “strong-buy” rating and set a $64.00 target price for the company in a research report on Monday, May 1st. Cowen and Company raised their target price on Baxter International from $48.00 to $57.00 and gave the stock a “market perform” rating in a research report on Monday, May 1st. Evercore ISI reaffirmed an “outperform” rating and issued a $60.00 target price (up from $57.00) on shares of Baxter International in a research report on Saturday, April 29th. Morgan Stanley raised their target price on Baxter International from $48.00 to $52.00 and gave the stock an “underweight” rating in a research report on Friday, April 28th. Finally, Royal Bank of Canada increased their price objective on Baxter International from $55.00 to $58.00 and gave the stock a “sector perform” rating in a research note on Thursday, April 27th.

Shares of Baxter International (NYSE:BAX) traded down 0.28% during midday trading on Friday, hitting $56.19. 228,539 shares of the stock were exchanged. The stock has a market cap of $30.55 billion, a P/E ratio of 16.63 and a beta of 0.77. The stock’s 50-day moving average price is $53.57 and its 200 day moving average price is $48.94. Baxter International has a one year low of $42.22 and a one year high of $56.50.

Baxter International (NYSE:BAX) last released its quarterly earnings data on Wednesday, April 26th. The medical instruments supplier reported $0.58 EPS for the quarter, topping analysts’ consensus estimates of $0.51 by $0.07. Baxter International had a return on equity of 12.35% and a net margin of 48.85%. The firm had revenue of $2.48 billion for the quarter, compared to the consensus estimate of $2.43 billion. During the same quarter in the prior year, the company posted $0.36 earnings per share. The firm’s revenue was up 4.2% on a year-over-year basis. On average, analysts anticipate that Baxter International will post $2.27 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, July 3rd. Investors of record on Friday, June 2nd will be issued a dividend of $0.16 per share. The ex-dividend date of this dividend is Wednesday, May 31st. This is a positive change from Baxter International’s previous quarterly dividend of $0.13. This represents a $0.64 dividend on an annualized basis and a dividend yield of 1.14%. Baxter International’s payout ratio is presently 5.78%.

In other news, SVP Brik V. Eyre sold 130,732 shares of the business’s stock in a transaction on Monday, May 8th. The stock was sold at an average price of $55.69, for a total transaction of $7,280,465.08. Following the completion of the transaction, the senior vice president now owns 49,966 shares of the company’s stock, valued at approximately $2,782,606.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Carole J. Shapazian sold 3,760 shares of the business’s stock in a transaction on Tuesday, May 9th. The stock was sold at an average price of $55.89, for a total value of $210,146.40. Following the transaction, the director now directly owns 16,226 shares of the company’s stock, valued at approximately $906,871.14. The disclosure for this sale can be found here. Insiders have sold a total of 147,332 shares of company stock worth $8,151,144 over the last three months. 1.08% of the stock is owned by insiders.

Several institutional investors have recently bought and sold shares of BAX. Reilly Financial Advisors LLC boosted its position in shares of Baxter International by 20.4% in the first quarter. Reilly Financial Advisors LLC now owns 2,054 shares of the medical instruments supplier’s stock worth $107,000 after buying an additional 348 shares during the last quarter. Quadrant Capital Group LLC boosted its position in shares of Baxter International by 1.3% in the first quarter. Quadrant Capital Group LLC now owns 2,344 shares of the medical instruments supplier’s stock worth $113,000 after buying an additional 31 shares during the last quarter. Harvest Fund Management Co. Ltd purchased a new position in shares of Baxter International during the fourth quarter worth about $120,000. Benjamin F. Edwards & Company Inc. boosted its position in shares of Baxter International by 6.1% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 2,533 shares of the medical instruments supplier’s stock worth $131,000 after buying an additional 145 shares during the last quarter. Finally, Bronfman E.L. Rothschild L.P. boosted its position in shares of Baxter International by 3.9% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 2,776 shares of the medical instruments supplier’s stock worth $144,000 after buying an additional 103 shares during the last quarter. 83.20% of the stock is owned by institutional investors.

About Baxter International

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Related posts

Leave a Comment